IDH2 and Langerhans cell histiocytosis: Since IDH2 mutations have not been reported in LCH but are well‐described in hematologic malignancies, targeted DNA‐based NGS was also performed on her peripheral blood using the 34‐gene Illumina TruSight Myeloid Panel.